DrugId:  1
1. Name:  Selenium Sulfide
2. Groups:  Approved
3. Description:  Selenium Sulfide is an antifungal agent as well as a cytostatic agent, slowing the growth of hyperproliferative cells in seborrhea. Selenium Sulfide is the active ingredient often used in shampoos for the treatment of dandruff, seborrheic dermatitis and tinea capitis, a fungal infection that is primarily a disease of preadolescent children.
4. Indication:  For treatment of tinea versicolor, tinea capitis, dandruff and seborrheic dermatitis of the scalp.
DrugId:  2
1. Name:  Mechlorethamine
2. Groups:  Approved, Investigational
3. Description:  A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. [PubChem]The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCL. 
4. Indication:  For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
DrugId:  3
1. Name:  BF-37
2. Groups:  Investigational
3. Description:  BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.
4. Indication:  Investigated for use/treatment in atopic dermatitis.
DrugId:  4
1. Name:  Fezakinumab
2. Groups:  Investigational
3. Description:  Fezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.
4. Indication:  Not Available
DrugId:  5
1. Name:  Stannous fluoride
2. Groups:  Approved
3. Description:  Stannous Fluoride, or Tn(II) Fluoride, is a compound commonly used in toothpastes for the prevention of gingivitis, dental infections, cavities, and to relieve dental hypersensitivity. Although similar in function and activity to Sodium Fluoride (NaF), the conventionally added ingredient in toothpastes, stannous fluoride has been shown to be more effective at stopping and reversing dental lesions [2]. It manages and prevents dental caries and gingivitis by promoting enamel mineralization [1], reducing gingival inflammation and bleeding [3, 4] through its potential broad-spectrum antibiotic effect and modulation of the microbial composition of the dental biofilm [2]. It is an FDA-approved over-the-counter product.
4. Indication:  Indicated for use to relieve dental hypersensitivity, increase enamel production, prevent gingivitis and cavities, and control periodontal infections. 
DrugId:  6
1. Name:  Maltodextrin
2. Groups:  Investigational
3. Description:  Maltodextrin is under investigation for the treatment and prevention of Autism, Pouchitis, Inflammation, Colonic Cancer, and Atopic Dermatitis, among others. Maltodextrin has been investigated for the prevention and treatment of Fatigue, Thalassemia, Constipation, Type I Diabetes, and Sickle Cell Anemia, among others.
4. Indication:  Not Available
DrugId:  7
1. Name:  Ligelizumab
2. Groups:  Investigational
3. Description:  Ligelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma, and Atopic Dermatitis, among others.
4. Indication:  Not Available
DrugId:  8
1. Name:  SRP 299
2. Groups:  Investigational
3. Description:  SRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation. Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 activity. A specific subset of serotonergic neurons in the interfascicular part of the dorsal raphe nucleus (DRI) is believed to be involved, based on studies with mice. 
4. Indication:  Investigated for use/treatment in asthma, atopic dermatitis, and pediatric atopic dermatitis indications.
DrugId:  9
1. Name:  AN0128
2. Groups:  Investigational
3. Description:  AN0128 is a novel compound that contains a boron atom within a borinic acid complex. AN0128 has broad spectrum activity against a wide variety of Gram positivebacteria, including many that are known skin colonizers. Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibioticresistance of P. acnes to standard antibiotics necessitates the development of new treatment agents. AN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis.
4. Indication:  Investigated for use/treatment in acne, atopic dermatitis, pediatric indications, and psoriasis and psoriatic disorders.
DrugId:  10
1. Name:  Cetyl alcohol
2. Groups:  Approved
3. Description:  Cetyl alcohol, also known as 1-hexadecanol or n-hexadecyl alcohol, is a 16-C fatty alcohol with the chemical formula CH3(CH2)15OH. It can be produced from the reduction of palmitic acid. Cetyl alcohol is present in a waxy white powder or flake form at room temperature, and is insoluble in water and soluble in alcohols and oils [1]. Discovered by Chevrenl in 1913, cetyl alcohol is one of the oldest known long-chain alcohol [1]. It may be contained in cosmetic and personal care products such as shampoos, creams and lotions. Mainly it is used as an opacifier, emulsifier, and thickening agent that alter the thickness of the liquid, and increase and stabilize the foaming capacity. Due to its water-binding property, cetyl alcohol is commonly used as an emollient that prevents drying and chapping of the skin [1]. According to the FDA Code of Federal Regulations, cetyl alcohol is a safe synthetic fatty acid in food and in the synthesis of food components under the condition that it contain not less than 98 percent of total alcohols and not less than 94 percent of straight chain alcohols [3]. Cetyl alcohol is also listed in the OTC ingredient list as a skin protectant for skin irritations caused by poison ivy, oak, sumac, and insect bites or stings [4]. Cetyl alcohol is reported to be a mild skin or eye irritant.
4. Indication:  No therapeutic indications in medicinal products. Indicated to be used as an indirect additive in food contact substances, or an ingredient in commercial or cosmetic products. 
DrugId:  11
1. Name:  Pimecrolimus
2. Groups:  Approved, Investigational
3. Description:  Pimecrolimus is an immunomodulating agent used in the treatment of atopic dermatitis (eczema). It is currently available as a topical cream, once marketed by Novartis, (however Galderma will be promoting the molecule in Canada in early 2007) under the trade name Elidel. [Wikipedia]
4. Indication:  For treatment of mild to moderate atopic dermatitis.
DrugId:  12
1. Name:  Lebrikizumab
2. Groups:  Investigational
3. Description:  Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
4. Indication:  Not Available
DrugId:  13
1. Name:  Vapitadine
2. Groups:  Investigational
3. Description:  Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
4. Indication:  Investigated for use/treatment in atopic dermatitis.
DrugId:  14
1. Name:  Chloroxine
2. Groups:  Approved
3. Description:  Chloroxine is a synthetic antibacterial compound. Chloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp.
4. Indication:  Used in the treatment of dandruff and mild to moderately severe seborrheic dermatitis of the scalp.
DrugId:  15
1. Name:  NPI 32101
2. Groups:  Investigational
3. Description:  NPI 32101 possesses both anti-inflammatory and broad spectrum antimicrobial activities. This combination of pharmacological properties may have additional therapeutic uses beyond dermatology.
4. Indication:  Atopic dermatitis
DrugId:  16
1. Name:  NCX 1022
2. Groups:  Investigational
3. Description:  NCX is an NO-releasing derivative of hydrocortisone.
4. Indication:  Investigated for use/treatment in atopic dermatitis.
DrugId:  17
1. Name:  Bergapten
2. Groups:  Investigational
3. Description:  Bergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).
4. Indication:  Not Available
DrugId:  18
1. Name:  Benzyl Benzoate
2. Groups:  Approved
3. Description:  Benzyl benzoate is one of the older preparations used to treat scabies. Scabies is a skin infection caused by the mite sarcoptes scabiei. It is characterised by severe itching (particularly at night), red spots, and may lead to a secondary infection. Benzyl benzoate is lethal to this mite and so is useful in the treatment of scabies. It is also used to treat lice infestation of the head and body. Benzyl benzoate is not the treatment of choice for scabies due to its irritant properties.
4. Indication:  Used to kill lice and the mites responsible for the skin condition scabies.
DrugId:  19
1. Name:  Mapracorat
2. Groups:  Investigational
3. Description:  Mapracorat has been investigated for the treatment of Eczema and Atopic Dermatitis.
4. Indication:  Not Available
DrugId:  20
1. Name:  AQX-1125
2. Groups:  Investigational
3. Description:  AQX-1125 has been used in trials studying the treatment of COPD, Atopic Dermatitis, Interstitial Cystitis, and Bladder Pain Syndrome.
4. Indication:  Not Available
DrugId:  21
1. Name:  E-6005
2. Groups:  Investigational
3. Description:  E6005 has been used in trials studying the treatment of Atopic Dermatitis.
4. Indication:  Not Available
DrugId:  22
1. Name:  Borage oil
2. Groups:  Approved, Investigational
3. Description:  Borage oil, or borage seed oil, is a rich source of gamma-linolenic acid (GLA) that is obtained from the seeds of the Borago officinalis (borage). Borage oil is used as an herbal treatment of skin disorders including eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although its clinical efficacy and long-term effects are not fully elucidated yet. GLA, which accounts for approximately 24% of the oil, is converted to dihomo-Î³-linolenic acid (DGLA) which acts as a precursor to anti-inflammatory mediators such as 1-series prostaglandins and the 3-series leukotrienes. Borage oil may be found in foods or in skin care products.
4. Indication:  Not Available
DrugId:  23
1. Name:  Fevipiprant
2. Groups:  Investigational
3. Description:  Fevipiprant has been used in trials studying the treatment of Asthma, Atopic Dermatitis, and Allergic Rhinitis.
4. Indication:  Not Available
DrugId:  24
1. Name:  Tradipitant
2. Groups:  Investigational
3. Description:  Tradipitant has been used in trials studying the treatment and prevention of Eczema, Pruritus, Gastroparesis, Chronic Pruritus, and Atopic Dermatitis, among others.
4. Indication:  Not Available
DrugId:  25
1. Name:  AVAC
2. Groups:  Investigational
3. Description:  AVAC is derived from M. vaccae. It has been tested in uses related to asthma and in treating eczema and atopic dermatitis.Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 activity.
4. Indication:  Investigated for use/treatment in asthma and atopic dermatitis.
